![]() |
Researchers at Penn State College of Medicine have identified a biomarker that can be used in blood tests to diagnose glioblastoma, the most common and deadliest type of brain cancer, and track its progression and guide treatment. Photo Credit: National Cancer Institute |
Glioblastoma (GBM) is the most common and deadliest type of brain cancer with a five-year survival rate of only 5%. Researchers at Penn State College of Medicine have identified a biomarker that can be used in blood tests to diagnose GBM, track its progression and guide treatment. The researchers said that such a non-invasive liquid biopsy for GBM could help patients get the care they need more quickly.
“Patients normally receive imaging, such as MRI or CT scans, to diagnose and track the progression of brain tumors, but it can be difficult for physicians to tell from those scans if the patient is getting better or worse because they don’t provide detail at the cellular or molecular level,” said Vladimir Khristov, graduate and medical student, Penn State. “That is why we need a supplemental diagnostic test to help physicians determine if the tumors are responding to therapy and regressing, or if they are getting worse and need additional treatment.”
Indeed, added Brad Zacharia, associate professor of neurosurgery and of otolaryngology, Penn State, a liquid biopsy for glioblastoma could be of tremendous value to patients suffering from this devastating tumor.